Glycated albumin is a better glycemic indicator than glycated hemoglobin values in hemodialysis patients with diabetes: Effect of anemia and erythropoietin injection

Journal of the American Society of Nephrology

Volumn 18, Issue 3, 2007, Pages 896-903

  Inaba, Masaaki ^a   Okuno, Senji ^b   Kumeda, Yasuro ^d   Yamada, Shinsuke ^a   Imanishi, Yasuo ^a   Tabata, Tsutomu ^c   Okamura, Mikio ^d   Okada, Shigeki ^e   Yamakawa, Tomoyuki ^b   Ishimura, Eiji ^a   Nishizawa, Yoshiki ^a  

^a OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b Shirasagi Hospital   (Japan)

^c Inoue Hospital   (Japan)

^d Ohno Memorial Hospital   (Japan)

^e Okada Clinic   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; GLUCOSE; GLYCOSYLATED ALBUMIN; GLYCOSYLATED HEMOGLOBIN; RECOMBINANT ERYTHROPOIETIN;

ALBUMIN BLOOD LEVEL; ANEMIA; ARTICLE; CORRELATION ANALYSIS; DIABETES MELLITUS; ERYTHROCYTE; EVALUATION; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEMODIALYSIS; HUMAN; INDEPENDENT VARIABLE; JAPAN; MAJOR CLINICAL STUDY; MULTIPLE REGRESSION; PRIORITY JOURNAL;

EID: 33947243803     PISSN: 10466673     EISSN: None     Source Type: Journal    
DOI: 10.1681/ASN.2006070772     Document Type: Article

References (31)

1. The Diabetes Control and Complications Trial Research Group: The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329: 977-986, 1993
2. The DCCT Research Group: Diabetes Control and Complications Trial (DCCT): Results of feasibility study. Diabetes Care 10: 1-19, 1987
3. Ohkubo Y, Kishikawa H, Araki E, Miyata T, Isami S, Motoyoshi S, Kojima Y, Furuyoshi N, Shichiri M: Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: A randomized prospective 6-year study. Diabetes Res Clin Pract 28: 103-117, 1995
4. UK Prospective Diabetes Study (UKPDS) Group: Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352: 837-853, 1998
5. Cao JJ, Hudson M, Jankowski M, Whitehouse F, Weaver WD: Relation of chronic and acute glycemic control on mortality in acute myocardial infarction with diabetes mellitus. Am J Cardiol 96: 183-186, 2005
6. Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O: Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 348: 383-393, 2003
7. Morioka T, Emoto M, Tabata T, Shoji T, Tahara H, Kishimoto H, Ishimura E, Nishizawa Y: Glycemic control is a predictor of survival for diabetic patients on hemodialysis. Diabetes Care 24: 909-913, 2001
8. Wu MS, Yu CC, Yang CW, Wu CH, Haung JY, Hong JJ, Fan Chiang CY, Huang CC, Leu ML: Poor pre-dialysis glycaemic control is a predictor of mortality in type II diabetic patients on maintenance haemodialysis. Nephrol Dial Transplant 12: 2105-2110, 1997
9. Ichikawa H, Nagake Y, Takahashi M, Nakazono H, Kawabata K, Shikata K, Makino H: What is the best index of glycemic control in patients with diabetes mellitus on hemodialysis? Nippon Jinzo Gakkai Shi 38: 305-308, 1996
10. Joy MS, Cefalu WT, Hogan SL, Nachman PH: Long-term glycemic control measurements in diabetic patients receiving hemodialysis. Am J Kidney Dis 39: 297-307, 2002
11. Nakao T, Matsumoto H, Okada T, Han M, Hidaka H, Yoshino M, Shino T, Yamada C, Nagaoka Y: Influence of erythropoietin treatment on hemoglobin A1c levels in patients with chronic renal failure on hemodialysis. Intern Med 38: 826-830, 1998
12. Kosecki SM, Rodgers PT, Adams MB: Glycemic monitoring in diabetics with sickle cell plus beta-thalassemia hemoglobinopathy. Ann Pharmacother 39: 1557-1560, 2005
13. Kouzuma T: Study of glycated amino acid elimination for an improved enzymatic glycated albumin measurement method. Clin Chim Acta 346: 135-143, 2004
14. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus: Report on the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 21[Suppl 1]: S5-S22, 2005
15. Inaba M, Okuno S, Imanishi Y, Yamada S, Shioi A, Yamakawa T, Ishimura E, Nishizawa Y: Role of fibroblast growth factor-23 in peripheral vascular calcification in non-diabetic and diabetic hemodialysis patients. Osteoporos Int 17: 1506-1513, 2006
16. Inaba M, Nagasue K, Okuno S, Ueda M, Kumeda Y, Imanishi Y, Shoji T, Ishimura E, Ohta T, Nakatani T, Kim M, Nishizawa Y: Impaired secretion of parathyroid hormone, but not refractoriness of osteoblast, is a major mechanism of low bone turnover in hemodialyzed patients with diabetes mellitus. Am J Kidney Dis 39: 1261-1269, 2002
17. Nagamine Y, Mitsui K, Nakao T, Matsumoto M, Fujita C, Doi T: Evaluation of the enzymatic method for glycated albumin with liquid type reagent (Lucia GA-L) [in Japanese]. Jpn J Med Pharm Sci 51: 737-745, 2004
18. Tominaga M, Makino H, Yoshino G, Kuwa K, Takei I, Aono Y, Hoshino T, Umemoto M, Shimatsu A, Sanke T, Kuwashima M, Taminato T, Ono J: Japanese standard reference material JDS Lot 2 for haemoglobin A1c. II: Present state of standardization of haemoglobin A1c in Japan using the new reference material in routine clinical assays. Ann. Clin Biochem 42: 47-50, 2005
19. Ichihara K: Statistics for Bioscience. Practical Technique and Theory, Tokyo, Nankodo Co. Ltd., 1990, pp 218-223
20. Tahara Y: Glycoalbumin [in Japanese], Kettouti wo Miru, Kangaeru, 2000, pp 62-69
21. Avignon A, Radauceanu A, Monnier L: Nonfasting plasma glucose is a better marker of diabetic control than fasting plasma glucose in type 2 diabetes. Diabetes Care 20: 1822-1826, 1997
22. Cohen MP: Nonenzymatic glycation: A central mechanism in diabetic microvasculopathy. J Diabet Complications 2: 214-217, 1988
23. Schleicher ED, Olgemoller B, Wiedenmann E, Gerbitz KD: Specific glycation of albumin depends on its half-life. Clin Chem 39: 625-628, 1993
24. Koenig RJ, Peterson CM, Jones RL, Saudek C, Lehrman M, Cerami A: Correlation of glucose regulation and hemoglobin A1c in diabetes mellitus. N Engl J Med 295: 417-420, 1978
25. Bunn HF, Gabbay KH, Gallop PM: The glycosylation of hemoglobin: Relevance to diabetes mellitus. Science 20: 21-27, 1978
26. Fitzgibbons JF, Koler RD, Jones RT: Red cell age-related changes of hemoglobins A1a+b and A1c in normal and diabetic subjects. J Clin Invest 58: 820-824, 1976
27. Pisoni RL, Bragg-Gresham JL, Young EW, Akizawa T, Asano Y, Locatelli F, Bommer J, Cruz JM, Kerr PG, Mendelssohn DC, Held PJ, Port FK: Anemia management and outcomes from 12 countries in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis 44: 94-111, 2004
28. Kennedy AL, Merimee TJ: Glycosylated serum protein and hemoglobin A1 levels to measure control glycemia. Ann Intern Med 95: 56-58, 1981
29. Cohen MP, Ziyadeh FN, Chen S: Amadori-modified glycated serum proteins and accelerated atherosclerosis in diabetes: Pathogenic and therapeutic implications. J Lab Clin Med 147: 211-219, 2006
30. Amore A, Cirna P, Conti G, Cerutti F, Bagheri N, Emancipator SN, Coppo R: Amadori-configurated albumin indices nitric oxide-dependent apoptosis of endothelial cells: A possible mechanism of diabetic vasculopathy. Nephrol Dial Transplant 19: 53-60, 2004
31. Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, Hadden D, Turner RC, Holman RR: Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): Prospective observational study. BMJ 321: 405-412, 2000